Genome&Company
KOSDAQ:314130
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genome&Company
KOSDAQ:314130
|
KR |
|
S
|
Solucorp Industries Ltd
OTC:SLUP
|
US |
|
F
|
First Dawood Properties Ltd
KAR:FDPL
|
PK |
|
C
|
Cairn Homes PLC
F:C5H
|
IE |
|
M
|
Medallion Resources Ltd
F:MRDN
|
CA |
|
Z
|
Zenovia Digital Exchange Corp
OTC:ZDEC
|
US |
|
E
|
Erayak Power Solution Group Inc
NASDAQ:RAYA
|
CN |
|
Resapp Health Ltd
ASX:RAP
|
AU |
|
H
|
Hit Kit Global Solutions Ltd
BSE:532359
|
IN |
|
A
|
Abion Inc
KOSDAQ:203400
|
KR |
|
D
|
Delko SA
WSE:DEL
|
PL |
|
A
|
Artistic Denim Mills Ltd
KAR:ADMM
|
PK |
|
W
|
Wheels India Ltd
NSE:WHEELS
|
IN |
|
ImExHS Ltd
ASX:IME
|
AU |
|
P
|
Panoramic Resources Ltd
SWB:YM1
|
AU |
|
R
|
Rex Minerals Ltd
OTC:RXRLF
|
AU |
Bankruptcy Probability
Genome&Company's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Genome&Company Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KR |
G
|
Genome&Company
KOSDAQ:314130
|
190.3B KRW |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
462.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
233.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
136.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
85.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
56.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
80.6B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Genome&Company's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Genome&Company has total debt of 2.2B KRW. This includes both short-term (0 KRW) and long-term (2.2B KRW) debt.
You can find a full breakdown on its Balance Sheet.
